

*For Losses:* Capacity and energy losses incurred in connection with the transmission and delivery of capacity and energy under this rate schedule shall be supplied by the customer in accordance with the contract or service agreement.

Rate Schedule CAP-NITS2  
Supersedes Rate Schedule CAP-NITS1

### United States Department of Energy Western Area Power Administration

#### Central Arizona Project

##### *Schedule of Rate(s) for Network Integration Transmission Service*

*Effective:* The first day of the first full billing period beginning on or after January 1, 2006, through December 31, 2010.

*Applicable:* The transmission customer shall compensate the CAP each month for Network Integration Transmission Service (NITS) pursuant to the applicable Network Integration Transmission Service Agreement and annual revenue requirement referred to below. The formula for the annual revenue requirement used to calculate the charges for this service under this schedule was promulgated and may be modified pursuant to applicable Federal laws, regulations, and policies.

The Desert Southwest Region (DSW) may modify the charges for NITS upon written notice to the transmission customer. DSW shall charge the transmission customer in accordance with the revenue requirement then in effect.

#### Formula Rate

Monthly Charge = Transmission Customer's Load-Ratio Share × (Revenue Requirement/12)

#### Calculated Rate

The NITS rate is calculated using a projected annual revenue requirement. Based on updated financial and load data, a recalculated revenue requirement will go into effect on January 1 of each year during the effective rate schedule period.

[FR Doc. E6-110 Filed 1-9-06; 8:45 am]

BILLING CODE 6450-01-P

### ENVIRONMENTAL PROTECTION AGENCY

[FRL-8020-5]

#### National Advisory Council for Environmental Policy and Technology Environmental Technology Subcommittee

**AGENCY:** Environmental Protection Agency (EPA).

**ACTION:** Notice of meeting.

**SUMMARY:** Under the Federal Advisory Committee Act, Public Law 92463, EPA gives notice of a meeting of the Environmental Technology Subcommittee of the National Advisory Council for Environmental Policy and Technology (NACEPT). NACEPT

provides advice and recommendations to the Administrator of EPA on a broad range of environmental policy, technology, and management issues. The Environmental Technology Subcommittee was formed to assist EPA in evaluating its current and potential role in the development and commercialization of environmental technologies by suggesting how to optimize existing EPA programs to facilitate the development of sustainable private sector technologies, and by suggesting alternative approaches to achieving these goals. The purpose of the meeting is to discuss the Subcommittee's recommendations on these issues. The Subcommittee will also discuss new issues that it may address in the future. A copy of the agenda for the meeting will be posted at <http://www.epa.gov/ocem/nacept/cal-nacept.htm>.

**DATES:** The NACEPT Environmental Technology Subcommittee will hold a two day open meeting on Thursday, January 19, from 9 a.m. to 5 p.m. and Friday, January 20, from 8:30 a.m. to 1:30 p.m. Due to extenuating circumstances, contractual arrangements of the meeting space were delayed.

**ADDRESSES:** The meeting will be held at the Madison Hotel, 1177 15th Street, NW., Washington, DC 20005. The meeting is open to the public, with limited seating on a first-come, first-served basis.

**FOR FURTHER INFORMATION CONTACT:** Mark Joyce, Designated Federal Officer, [joyce.mark@epa.gov](mailto:joyce.mark@epa.gov), 202-233-0068, U.S. EPA, Office of Cooperative Environmental Management (1601E), 1200 Pennsylvania Avenue, NW., Washington, DC 20460.

**SUPPLEMENTARY INFORMATION:** Requests to make oral comments or provide written comments to the Subcommittee should be sent to Mark Joyce, Designated Federal Officer, at the contact information above. The public is welcome to attend all portions of the meeting.

*Meeting Access:* For information on access or services for individuals with disabilities, please contact Mark Joyce at 202-233-0068 or [joyce.mark@epa.gov](mailto:joyce.mark@epa.gov). To request accommodation of a disability, please contact Mark Joyce, preferably at least 10 days prior to the meeting, to give EPA as much time as possible to process your request.

Dated: January 4, 2006.

**Sonia Altieri,**

*Designated Federal Officer.*

[FR Doc. E6-98 Filed 1-9-06; 8:45 am]

BILLING CODE 6560-50-P

### ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPPT-2003-0006; FRL-7746-6]

#### TSCA Chemical Testing; Receipt of Test Data

**AGENCY:** Environmental Protection Agency (EPA).

**ACTION:** Notice.

**SUMMARY:** This notice announces EPA's receipt of test data regarding *In Vitro* Dermal Absorption Rate Testing of Certain Chemicals of Interest to the Occupational Safety and Health Administration. Data were received on the following chemicals: Biphenyl (CAS No. 92-52-4); tert-butylcatechol (TBC) (CAS No. 98-29-3); carbon disulfide (CAS No. 75-15-0); catechol (CAS No. 120-80-9); chlorobenzene (CAS No. 108-90-7); cyclohexanol (CAS No. 108-93-0); p-dichlorobenzene (CAS No. 106-46-7); dimethylacetamide (DMAc) (CAS No. 127-19-5); ethylene dichloride (CAS No. 107-06-2); hydroquinone monomethyl ether (HQMME) (CAS No. 150-76-5); methyl formate (CAS No. 107-31-3); vinyl toluene (CAS No. 25013-15-4); and p-xylene (CAS No. 106-42-3). These data were submitted pursuant to a test rule issued by EPA under section 4 of the Toxic Substances Control Act (TSCA).

**FOR FURTHER INFORMATION CONTACT:** Colby Lintner, Regulatory Coordinator, Environmental Assistance Division (7408M), Office of Pollution Prevention and Toxics, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone number: (202) 554-1404; e-mail address: [TSCA-Hotline@epa.gov](mailto:TSCA-Hotline@epa.gov).

#### SUPPLEMENTARY INFORMATION:

##### I. General Information

###### A. Does this Action Apply to Me?

This action is directed to the public in general. This action may, however, be of interest to those persons who are concerned about data on health and/or environmental effects and other characteristics of this chemical. Since other entities may also be interested, the Agency has not attempted to describe all the specific entities that may be affected by this action. If you have any questions regarding the applicability of this action to a particular entity, consult the person listed under **FOR FURTHER INFORMATION CONTACT**.

###### B. How Can I Get Copies of this Document and Other Related Information?

1. *Docket.* EPA has established an official public docket for this action under docket identification (ID) number

EPA-HQ-OPPT-2003-0006. The official public docket consists of the documents specifically referenced in this action, any public comments received, and other information related to this action. Although a part of the official docket, the public docket does not include Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. The official public docket is the collection of materials that is available for public viewing at the EPA Docket Center, Rm. B102-Reading Room, EPA West, 1301 Constitution Ave., NW., Washington, DC. The EPA Docket Center is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The EPA Docket Center Reading Room telephone number is (202) 566-1744 and the telephone number for the OPPT Docket, which is located in EPA Docket Center, is (202) 566-0280.

2. *Electronic access.* You may access this **Federal Register** document electronically through the EPA Internet under the "**Federal Register**" listings at <http://www.epa.gov/fedrgrstr/>.

*Agency Website:* EPADOCKET, EPA's electronic public docket and comment system was replaced on November 25, 2005, by an enhanced federal-wide electronic docket management and comment system located at <http://www.regulations.gov/>. Follow the on-line instructions.

An electronic version of the public docket is available through EPA's electronic public docket and comment system, EPA Dockets. You may use EPA Dockets at <http://www.epa.gov/edocket/> to submit or view public comments, access the index listing of the contents of the official public docket, and to access those documents in the public docket that are available electronically. Although not all docket materials may be available electronically, you may still access any of the publicly available docket materials through the docket facility identified in Unit I.B.1. Once in the system, select "search," then key in the appropriate docket ID number.

## II. Test Data Submissions

Section 4(d) of TSCA requires EPA to publish a notice in the **Federal Register** reporting the receipt of test data submitted pursuant to test rules promulgated under section 4(a) within 15 days after these data are received by EPA.

1. Test data for biphenyl were submitted by the Biphenyl Work Group and received by EPA on June 17, 2005. The submission includes a final study report submission titled: "*In Vitro* Dermal Absorption Rate Testing." (See

document ID No. EPA-HQ-2003-0006-0273.) The submission also includes a letter clarifying that the Biphenyl Work Group is not claiming trade secrecy or confidentiality on this report.

2. Test data for TBC were submitted by the Tertiary-Butylcatechol Consortium and received by EPA on July 20, 2005. The submission includes a final report titled: "[<sup>14</sup>C] Tert-Butylcatechol (TBC): Percutaneous Penetration of [<sup>14</sup>C] Tert-Butylcatechol Through Human Split-thickness Skin Membranes (*in-vitro*)." (See document ID No. EPA-HQ-2003-0006-0284.)

3. Test data for carbon disulfide were submitted by the Carbon Disulfide Dermal Absorption Task Group (Task Group) of the American Chemistry Council and received by EPA on August 15, 2005. The submission includes an appended final study report titled: "Carbon Disulfide: *In Vitro* Dermal Absorption Rate Testing." (See document ID No. EPA-HQ-2003-0006-0289.)

4. Test data on catechol were submitted by the Catechol Consortium and received by EPA on August 26, 2005. The submission includes a final study report titled "[<sup>14</sup>C] Catechol: Percutaneous Penetration of [<sup>14</sup>C] Catechol Through Human Split-thickness Skin Membranes (*in-vitro*)." (See document ID No. EPA-HQ-2003-0006-0287.)

5. Test data for chlorobenzene were submitted by the Chlorobenzene Producers Association (CPA) and received by EPA on June 6, 2005. The submission includes a final study report titled "Chlorobenzene: *In Vitro* Dermal Absorption Rate Testing." (See document ID No. EPA-HQ-2003-0006-0255.)

6. Test data for cyclohexanol were submitted on behalf of the Cyclohexanol Dermal Absorption Testing Committee and received by EPA on August 29, 2005. The submission includes a final study report from SafePharm Laboratories titled: "The *In Vitro* Dermal Absorption of [<sup>14</sup>C] Cyclohexanol through Human Skin." (See document ID No. EPA-HQ-2003-0006-0286.)

7. Test data for p-dichlorobenzene were submitted by the Chlorobenzene Producers Association and received by EPA on June 6, 2005. The submission includes a final study report titled: "p-Dichlorobenzene: *In Vitro* Dermal Absorption Rate Testing." (See document ID No. EPA-HQ-2003-0006-0255.)

8. Test data for DMAc were submitted by DuPont Chemical Solutions Enterprise and received by EPA on June 21, 2005. The submission includes a

final study report titled: "Dimethylacetamide: *In Vitro* Dermal Absorption Rate Testing." (See document ID No. EPA-HQ-2003-0006-0274.)

9. Test data for ethylene dichloride were submitted by the Hazardous Air Pollutant (HAP) Task Force and received by EPA on June 24, 2005. The submission includes a final study report titled: "Ethylene Dichloride: *In Vitro* Dermal Absorption Rate Testing." (See document ID No. EPA-HQ-2003-0006-0280.)

10. Test data for HQMME were submitted by the Hydroquinone Monomethyl Ether Dermal Absorption Task Group (Task Group) of the American Chemistry Council Hydroquinone Precursors and Derivatives Panel, and received by EPA on September 27, 2005. The submission includes an appended final study report titled: "Hydroquinone Monomethyl Ether: Measurement of the *In Vitro* Rate of Percutaneous Absorption Through Human Skin." (See document ID No. EPA-HQ-2003-0006-0293.)

11. Test data for methyl formate were submitted by Celanese Chemicals and received by EPA on July 18, 2005. The submission includes a final study report titled: "Methyl Formate: *In Vitro* Dermal Absorption Rate Testing." (See document ID Nos. EPA-HQ-2003-0006-0281 and EPA-HQ-2003-0006-0282.) The submission also includes a letter clarifying that Celanese is not claiming confidentiality on this report.

12. Test data for vinyl toluene were submitted on behalf of Deltech Corporation by the University of Louisiana and received by EPA on April 4, 2005. The submission includes a final study report submission titled: "Vinyl Toluene: *In Vitro* Dermal Absorption Rate Testing." (See document ID Nos. EPA-HQ-2003-0006-0247 and EPA-HQ-2003-0006-0248.) The submission also includes two letters clarifying that the study is not claimed confidential or trade secret.

13. Test data for p-xylene were submitted by the p-Xylene Dermal Absorption Task Group of the American Chemistry Council and received by EPA on September 27, 2005. The submission includes an appended final study report titled: "p-Xylene: *In Vitro* Dermal Absorption Rate Testing." (See document ID No. EPA-HQ-2003-0006-0291.)

These chemical substances are used in a wide variety of applications as industrial solvents, which may result in exposures of a substantial number of workers as described in the support document for the Proposed Rule (64 FR

31074, June 9, 1999, Table 3 - Exposure Information for Chemical Substances). EPA has initiated its review and evaluation process for these submissions. At this time, the Agency is unable to provide any determination as to the completeness of the submissions.

Authority: 15 U.S.C. 2603.

**List of Subjects**

Environmental protection, Hazardous substances.

Dated: December 29, 2005.

**Jim Willis,**

Director, Chemical Control Division, Office of Pollution Prevention and Toxics.

[FR Doc. E6-100 Filed 1-9-06; 8:45 am]

BILLING CODE 6560-50-S

**FEDERAL TRADE COMMISSION**

**Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules**

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodine Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration

and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

Trans No.	Acquiring	Acquired	Entities
<b>Transactions Granted Early Termination—12/05/2005</b>			
20060211 .....	Novartis AG .....	Chiron Corporation .....	Chiron Corporation.
20060214 .....	MVP Health Plan, Inc .....	Preferred Care, Inc .....	Preferred Care, Inc.
20060220 .....	Allis-Chalmers Energy Inc .....	Joe Van Matre .....	Specialty Rental Tools Inc.
20060224 .....	Josue Christiano Gomes da Silva .....	Spring Global S.A. ....	Springs Global S.A.
20060229 .....	KKR European Fund II, Limited Partnership.	Vestar-AIV Holdings A L.P. ....	FL Spring, S.p.A.
20060235 .....	Roger S. Penske .....	Stephen P. Cushman .....	Cush A-KM, Inc., Cush Enterprises, Cush H-E, Inc., Cush J-KM, Inc., Cush M-E, Inc., M.S.M. Group, Inc.
20060237 .....	Hanson PLC .....	PaverModule, Inc. ....	PaverModule, Inc.
20060240 .....	Horizon Health Corporation .....	P. Byron DeFoor .....	Delaware Investment Associates, LLC, Focus Healthcare, LLC, Focus Healthcare of Delaware, LLC, Focus Health of Florida, LLC, Focus Healthcare of Georgia, LLC, Focus Healthcare of Ohio, LLC, Highpoint Investment, LLC.
20060241 .....	Ronald B. Dana .....	Rex V. Ecoff .....	Liquid Transport Corp.
20060242 .....	Francisco Partners, L.P. ....	FrontRange Limited .....	Cayo Communications, Inc., FrontRange Solutions Inc.
20060259 .....	Lodge Holdco I LLC .....	La Quinta Corporation .....	La Quinta Corporation.
20060264 .....	Berkshire Fund VI, L.P. ....	PDS Associates, Inc. ....	PDS Associates, Inc.
20060267 .....	GUS plc .....	PriceGrabber.com, LLC .....	PriceGrabber.com, LLC.
<b>Transactions Granted Early Termination—12/06/2005</b>			
20060215 .....	Aleris International, Inc. ....	Ormet Corporation .....	Ormet Corporation.
20060275 .....	Jones Lang LaSalle Incorporation ....	Spaulding and Slye Partner LLC .....	Spaulding and Slye LLC.
<b>Transactions Granted Early Termination—12/08/2005</b>			
20060256 .....	U.S. Bancorp .....	Wachovia Corporation .....	Delaware Trust Company, National Association, Wachovia Bank and Trust Company (Cayman) Ltd., Wachovia Bank, National Association, Wachovia Bank of Delaware, National Association, Wachovia Trust Company of California.
20060277 .....	Avnet, Inc. ....	Calence, LLC .....	Calence, LLC.
20060279 .....	General Atlantic Partners 82, L.P. ....	NYMEX Holdings, Inc. ....	NYMEX Holdings, Inc.
<b>Transactions Granted Early Termination—12/09/2005</b>			
20060253 .....	Goense Bounds & Partners A, L.P. ..	Frank Scardino .....	Capital Drywall, Inc.
20060254 .....	Goense Bounds & Partners A, L.P. ..	James R. Gates and Angela Gates ..	Capital Drywall, Inc.
20060282 .....	Aetna Inc. ....	Express Scripts, Inc. ....	Aetna Specialty Pharmacy, LLC.
20060285 .....	Merrill Corporation .....	WordWave, Inc. ....	WordWave, Inc.